Aravindan Vasudevan (@aravasudevan) 's Twitter Profile
Aravindan Vasudevan

@aravasudevan

Scientist by heart, entrepreneur by spirit, and eternal seeker of knowledge

Passionate about innovation in #Oncology | Co-founder of @onecelldx and @actorius

ID: 765021068977442816

linkhttp://www.oncodiscover.com calendar_today15-08-2016 03:03:31

1,1K Tweet

398 Followers

826 Following

Yüksel Ürün (@dryukselurun) 's Twitter Profile Photo

Thrilled to share our new analysis from CheckMate 901! 🟡In N+ only metastatic UC, Nivolumab + chemo doubled complete response rate vs chemo alone (63% vs 34%) and prolonged PFS (HR 0.38) and OS (HR 0.58). ➡️A new horizon for a distinct subgroup. European Urology OncoAlert

Thrilled to share our new analysis from CheckMate 901!
🟡In N+ only metastatic UC, Nivolumab + chemo doubled complete response rate vs chemo alone (63% vs 34%) and prolonged PFS (HR 0.38) and OS (HR 0.58).
➡️A new horizon for a distinct subgroup.
<a href="/EUplatinum/">European Urology</a> <a href="/OncoAlert/">OncoAlert</a>
Pashtoon Kasi MD, MS (@pashtoonkasi) 's Twitter Profile Photo

Myriam Chalabi OncoAlert 🔑 Cannot over-emphasize that mismatch repair ✅MMR 🔬 testing should be done in 💯% of patients with colorectal cancers BEFORE any treatment decisions are made. There’s a reason why this was the 1st agnostic approval. OncoAlert #ASCO25

Pashtoon Kasi MD, MS (@pashtoonkasi) 's Twitter Profile Photo

💡☝🏽Broad panel-based NGS genomic testing🧬for non-metastatic #ColorectalCancer should be in the guidelines: We have ▪️PIK3CA consider testing statement➡️Aspirin💊 Don’t miss your ▪️MSS POL-E patient🟰immunotherapy💉 BRAF, HER2, MSI, & 🔜KRAS for adjuvant➕trials. OncoAlert

💡☝🏽Broad panel-based NGS genomic testing🧬for non-metastatic #ColorectalCancer should be in the guidelines:

We have
▪️PIK3CA consider testing statement➡️Aspirin💊

Don’t miss your
▪️MSS POL-E patient🟰immunotherapy💉 

BRAF, HER2, MSI, &amp; 🔜KRAS for adjuvant➕trials.

<a href="/OncoAlert/">OncoAlert</a>
Yüksel Ürün (@dryukselurun) 's Twitter Profile Photo

🧬 Which genes matter most in breast cancer testing? ESMO recommends a focused panel (BRCA1/2, PALB2, RAD51C/D, BRIP1, TP53) for routine germline testing in BC. ESMO - Eur. Oncology G Curigliano MD PhD FabriceAndre #esmo OncoAlert Oncology Brothers dailyreporter.esmo.org/news/experts-r…

🧬 Which genes matter most in breast cancer testing?
ESMO recommends a focused panel (BRCA1/2, PALB2, RAD51C/D, BRIP1, TP53) for routine germline testing in BC. 
<a href="/myESMO/">ESMO - Eur. Oncology</a> <a href="/curijoey/">G Curigliano MD PhD</a> <a href="/FAndreMD/">FabriceAndre</a> #esmo <a href="/OncoAlert/">OncoAlert</a> <a href="/OncBrothers/">Oncology Brothers</a> 
dailyreporter.esmo.org/news/experts-r…
Pashtoon Kasi MD, MS (@pashtoonkasi) 's Twitter Profile Photo

#LiquidBiopsies👇🏽this is 🆒! 💡Less about the assay but more about the approach/science. For patients getting liquid biopsies (#ctDNA), good idea by companies reporting other relevant biomarkers. ✔️Secondary germline🧬 ✔️Pharmacogenomics💊 ✔️HLA🩸 ✔️Viral e.g. HPV🦠 OncoAlert

#LiquidBiopsies👇🏽this is 🆒!

💡Less about the assay but more about the approach/science. For patients getting liquid biopsies (#ctDNA), good idea by companies reporting other relevant biomarkers.

✔️Secondary germline🧬
✔️Pharmacogenomics💊
✔️HLA🩸
✔️Viral e.g. HPV🦠

<a href="/OncoAlert/">OncoAlert</a>
Aravindan Vasudevan (@aravasudevan) 's Twitter Profile Photo

🧬 Precision oncology in India is undergoing a silent revolution. From react & respond ➡️ predict & prevent. Here’s how we’re rewriting the rules of cancer care. 👇 #CancerDiagnostics #Genomics #India

🧬 Precision oncology in India is undergoing a silent revolution.
From react &amp; respond ➡️ predict &amp; prevent.
Here’s how we’re rewriting the rules of cancer care. 👇
#CancerDiagnostics #Genomics #India